The stimulation of specific immune responses by Aβ and its adverse effect on tau pathology and neuronal survival has implications for immunotherapy in the treatment of AD (Higuchi et al., 2010; Maeda et al., 2011). This evidence concerns the gene MAPT and Alzheimer disease.